BioSante Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 115

BioSante Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “BioSante Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the BioSante Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, BioSante Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from BioSante Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- BioSante Pharmaceuticals, Inc. - Brief BioSante Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioSante Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioSante Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioSante Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BioSante Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioSante Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioSante Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioSante Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioSante Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of BioSante Pharmaceuticals, Inc.; BioSante Pharmaceuticals, Inc. - Key Therapeutics; BioSante Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; BioSante Pharmaceuticals, Inc. - News; BioSante Pharmaceuticals, Inc. - Latest Updates; BioSante Pharmaceuticals, Inc. - Pipeline; BioSante Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
BioSante Pharmaceuticals, Inc. Snapshot
BioSante Pharmaceuticals, Inc. Overview
Key Information
Key Facts
BioSante Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
BioSante Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
BioSante Pharmaceuticals, Inc. – Pipeline Products Glance
BioSante Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
BioSante Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
BioSante Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
BioSante Pharmaceuticals, Inc. – Drug Profiles
CG7060
Product Description
Mechanism of Action
R&D Progress
GVAX AML Vaccine
Product Description
Mechanism of Action
R&D Progress
GVAX Breast Cancer Vaccine
Product Description
Mechanism of Action
R&D Progress
GVAX CML Vaccine
Product Description
Mechanism of Action
R&D Progress
GVAX Melanoma
Product Description
Mechanism of Action
R&D Progress
GVAX Multiple Myeloma Vaccine
Product Description
Mechanism of Action
R&D Progress
LibiGel
Product Description
Mechanism of Action
R&D Progress
Pill-Plus
Product Description
Mechanism of Action
R&D Progress
BioSante Pharmaceuticals, Inc. – Pipeline Analysis
BioSante Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
BioSante Pharmaceuticals, Inc. - Pipeline Products By Target
BioSante Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
BioSante Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
BioSante Pharmaceuticals, Inc. – Recent Pipeline Updates
BioSante Pharmaceuticals, Inc. - Dormant Projects
BioSante Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
CG8840
CG7870
CG7870 + Docetaxel
CG8123
CG8123 + Cyclophosphamide
GVAX Immunotherapy + Docetaxel
GVAX Immunotherapy + Ipilimumab
BioSante Pharmaceuticals, Inc. – Company Statement
BioSante Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
May 31, 2011: BioSante Pharmaceuticals Completes Enrollment In LibiGel Phase III Safety Study
Jun 30, 2010: BioSante Announces Positive Results From Pill-Plus Oral Contraceptive Phase II Study
Mar 30, 2011: BioSante Pharmaceuticals Completes Enrollment In Both Pivotal LibiGel Phase III Efficacy Trials
Dec 28, 2006: BioSante Pharmaceuticals Initiates Phase III Study Of LibiGel (Transdermal Testosterone Gel) In The Treatment Of Female Sexual Dysfunction
Oct 26, 2010: BioSante Reports Positive LibiGel Data Monitoring Committee Recommendation
Oct 25, 2010: BioSante Reports Positive LibiGel Data Monitoring Committee Recommendation
Jan 25, 2011: BioSante Receives FDA Orphan Drug Designation For Melanoma Cancer Vaccine
Feb 24, 2011: BioSante Pharmaceuticals Completes Enrollment In LibiGel Phase III Efficacy Trial
Mar 23, 2010: BioSante Announces Additional Positive Leukemia Vaccine Results And Second FDA Orphan Drug Designation
Jun 21, 2010: BioSante Pharmaceuticals Says FDA Advisory Committee Recommendation Against Flibanserin Has No Impact On LibiGel
Jun 21, 2010: BioSante Reports Positive LibiGel Safety Data In Phase III Clinical Program
Jun 19, 2007: BioSante Pharmaceuticals Announces Oral Contraceptive Phase II Study Initiation
Mar 19, 2008: BioSante Pharmaceuticals Initiates Third LibiGel Phase III Trial In The Treatment Of Female Sexual Dysfunction Under An SPA
Oct 18, 2010: BioSante Reaches Key LibiGel Safety Study Enrollment Target
Aug 18, 2004: Cell Genesys Launches Phase I/II Trial Of CG7870 In Combination With Taxotere For Advanced Prostate Cancer
Jun 18, 2010: BioSante To Present LibiGel Safety Update At ENDO Annual Meeting
Feb 18, 2010: BioSante Pharmaceuticals To Present LibiGel Clinical Update At ISSWSH Conference
Jun 17, 2009: Antares Pharma Announces Partners Update Of LibiGel Safety Study
Dec 14, 2001: Cell Genesys Updates Clinical Results Of Phase I/II Trial Of CG7870 In Advanced Prostate Cancer
Feb 14, 2011: BioSante Pharmaceuticals To Present LibiGel Safety Study Update At BIO CEO & Investor Conference
Jul 13, 2010: BioSante Initiates LibiGel Study For Cognitive Function In Women
Sep 12, 2011: BioSante Pharmaceuticals Successfully Completes LibiGel Pharmacokinetic Study
Feb 12, 2008: Antares Receives Positive Guidance For European Registration
Oct 11, 2011: BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review In Phase III Program
Oct 11, 2010: BioSante Presents LibiGel Clinical Study Update At North American Menopause Society Meeting
Mar 10, 2010: BioSante Announces Positive Leukemia Vaccine Results
May 07, 2007: BioSante Pharmaceuticals Signs Oral Contraceptive License with Pantarhei Bioscience
Jun 06, 2011: FDA Lifts Clinical Hold On BioSante's GVAX Prostate Cancer Vaccine
Oct 04, 2011: BioSante Completes Both Pivotal LibiGel Efficacy Trials
Oct 04, 2010: BioSante To Present LibiGel Clinical Trial Update At North American Menopause Society Meeting 2010
Apr 04, 2011: BioSante Pharmaceuticals To Host LibiGel R&D Event In New York City
Nov 02, 2005: BioSante Pharmaceuticals Comments On Updated FDA Guidance For Testosterone Therapy
Feb 02, 2011: BioSante Pharmaceuticals To Provide Update On LibiGel Safety Study At ISSWSH Meeting
Aug 01, 2002: Cell Genesys Issued Patent for Oncolytic Virus.
Financial Deals Landscape
BioSante Pharmaceuticals, Inc., Deals Summary
BioSante Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
BioSante Acquires Elestrin Royalty From Azur Pharma
BioSante Pharmaceuticals Reacquires Elestrin From Nycomed
Partnerships
BioSante Pharmaceuticals Signs An Agreement With PharmaSwiss
BioSante Pharmaceuticals Signs An Agreement With Azur Pharma
BioSante Pharmaceuticals Signs An Agreement With Pantarhei Bioscience
BioSante Pharmaceuticals Signs An Agreement With Bradley Pharmaceuticals
BioSante Enters Into Co-Development Agreement With US Army Medical Research Institute
Merger
BioSante Pharmaceuticals Merges With Cell Genesys
Licensing Agreements
BioSante Pharmaceuticals Signs An Agreement With A European Pharmaceutical Company
BioSante Pharmaceuticals Enters Into Licensing Agreement With The John P. Hussman Foundation
BioSante Pharmaceuticals Enters Into Licensing Agreement With Aduro BioTech
BioSante Pharmaceuticals Enters Into Licensing Agreement With Cold Genesys
BioSante Pharmaceuticals Enters Into Licensing Agreement With Medical Aesthetic
BioSante Pharmaceuticals Amends License Agreement With Teva Pharmaceutical
BioSante Pharmaceuticals Signs An Agreement With Medical Aesthetics Technology
BioSante Pharmaceuticals Enters Into An Licensing Agreement With Wake Forest University And Cedars-Sinai
Equity Offering
BioSante Pharmaceuticals Completes Underwritten Public Offering Of Common Stock For $48 Million
BioSante Pharmaceuticals Files Registration Statement For Public Offering Of $150 Million
BioSante Pharmaceuticals Completes Registered Direct Offering Of Units For $25.1 Million
BioSante Pharmaceuticals Completes Registered Direct Offering Of Units For $18 Million
BioSante Pharmaceuticals Completes Registered Direct Offering Of $15 Million
BioSante Pharmaceuticals Files Resiatration Statement For Public Offering Of $75 Million
BioSante Pharmaceuticals Completed Registered Direct Offering Of $18 Million
BioSante Completes Public Offering Of $12 Million
BioSante Pharmaceuticals Completes Private Placement Of $18.33 Million
Cell Genesys Completes Registered Direct Offering Of $60 Million
Cell Genesys Completes Private Placement Of $75 Million
BioSante Pharmaceuticals Completes Public Offering Of $29.1 Million
BioSante Pharmaceuticals Completes Private Placement Of $7.62 Million
BioSante Pharmaceuticals Completes Private Placement Of $17.7 Million
Cell Genesys Completes Public Offering Of $61.1 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
BioSante Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
BioSante Pharmaceuticals, Inc. – Phase III, H2 2011
BioSante Pharmaceuticals, Inc. - Phase II, H2 2011
BioSante Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
BioSante Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
BioSante Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
BioSante Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
BioSante Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
BioSante Pharmaceuticals, Inc., Other Locations
BioSante Pharmaceuticals, Inc., Deals Summary
BioSante Acquires Elestrin Royalty From Azur Pharma
BioSante Pharmaceuticals Reacquires Elestrin From Nycomed
BioSante Pharmaceuticals Signs An Agreement With PharmaSwiss
BioSante Pharmaceuticals Signs An Agreement With Azur Pharma
BioSante Pharmaceuticals Signs An Agreement With Pantarhei Bioscience
BioSante Pharmaceuticals Signs An Agreement With Bradley Pharmaceuticals
BioSante Enters Into Co-Development Agreement With US Army Medical Research Institute
BioSante Pharmaceuticals Merges With Cell Genesys
BioSante Pharmaceuticals Signs An Agreement With A European Pharmaceutical Company
BioSante Pharmaceuticals Enters Into Licensing Agreement With The John P. Hussman Foundation
BioSante Pharmaceuticals Enters Into Licensing Agreement With Aduro BioTech
BioSante Pharmaceuticals Enters Into Licensing Agreement With Cold Genesys
BioSante Pharmaceuticals Enters Into Licensing Agreement With Medical Aesthetic
BioSante Pharmaceuticals Amends License Agreement With Teva Pharmaceutical
BioSante Pharmaceuticals Signs An Agreement With Medical Aesthetics Technology
BioSante Pharmaceuticals Enters Into An Licensing Agreement With Wake Forest University And Cedars-Sinai
BioSante Pharmaceuticals Completes Underwritten Public Offering Of Common Stock For $48 Million
BioSante Pharmaceuticals Files Registration Statement For Public Offering Of $150 Million
BioSante Pharmaceuticals Completes Registered Direct Offering Of Units For $25.1 Million
BioSante Pharmaceuticals Completes Registered Direct Offering Of Units For $18 Million
BioSante Pharmaceuticals Completes Registered Direct Offering Of $15 Million
BioSante Pharmaceuticals Files Resiatration Statement For Public Offering Of $75 Million
BioSante Pharmaceuticals Completed Registered Direct Offering Of $18 Million
BioSante Completes Public Offering Of $12 Million
BioSante Pharmaceuticals Completes Private Placement Of $18.33 Million
Cell Genesys Completes Registered Direct Offering Of $60 Million
Cell Genesys Completes Private Placement Of $75 Million
BioSante Pharmaceuticals Completes Public Offering Of $29.1 Million
BioSante Pharmaceuticals Completes Private Placement Of $7.62 Million
BioSante Pharmaceuticals Completes Private Placement Of $17.7 Million
Cell Genesys Completes Public Offering Of $61.1 Million

List of Figures
BioSante Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
BioSante Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
BioSante Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• Analysis of Google Inc